CHICAGO--(BUSINESS WIRE)--Emerging medical device manufacturing company, Advanced Cooling Therapy (ACT), has received CE marking for its first product, the Esophageal Cooling Device (ECD) to control patient temperature. The product is now available to medical professionals in Europe.
The ECD is a single use, fully-enclosed triple lumen system that is inserted into the esophagus to modulate and control patient temperature when clinically indicated. Two lumens attach to existing temperature modulation equipment while a third lumen simultaneously allows gastric decompression and drainage. The ECD can be rapidly inserted by most trained health care professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or ICU. No other product on the market is approved to use the esophageal environment for whole-body temperature modulation.
ACT’s President and Co-Founder, Erik Kulstad, MD, MS, said, “As an Emergency Room physician, I know intimately the challenges associated with traditional temperature management – bulky blankets, expensive machines, and invasive catheter procedures. The ECD is safe, easy to use, and cost-effective, and we look forward to commercialization in Europe with the CE marking.”
CE marking indicates a product complies with EU legislation and enables the free movement of products within the European market. CE marking applies to the use of the ECD in participating European Economic Area countries only and does not apply in the US.
Advanced Cooling Therapy’s novel technology platform provides improved methods to control patient temperature where clinically indicated using the esophageal environment.